Join        Login             Stock Quote

Biostar Pharma (BSPM) To Manufacture 16 New Drugs For Xijing Military Hospital

 December 04, 2012 09:09 AM

(By Balaseshan) Biostar Pharmaceuticals Inc. (NASDAQ: BSPM) said it has signed another one-year agreement valued at about $8 million to manufacture and supply 16 new drugs for Xijing Military Hospital.

Biostar said the new drugs will be used to treat a variety of diseases such as pharyngitis, nasopharynx, gastroenteropathy, nephropathy, asthma, hyperplasia of mammary glands, dermatosis, gynecological diseases, etc.

The material terms of this agreement are similar to those of the first two one-year agreements signed with the same hospital in September and October 2012 for $3.6 million and $3.0 million, respectively.

[Related -Earning Scan: LOW, HIHO, BSPM, SORL, NLST, HSFT]

With this new agreement, Biostar will be manufacturing a total of 24 drugs for Xijing Military Hospital (10 granules, 13 capsules, and one powder drug) with a combined value of $14.6 million.

"The signing of these agreements is a result of our hard work to quickly complete experimental tests, trial production, and pass manufacturing technology and quality inspections. These types of contracts have the potential to generate substantial revenues, have very low sales expenses and a much shorter sales cycle," said Ronghua Wang, Chief Executive of Biostar.

The company said the agreements mark the initial step of its strategic partnership with The Fourth Military Medical University (FMMU), one of China's most prestigious military medical universities and research centers.

"As previously announced, we are working to become a strategic partner of FMMU in the fields of research and product development and also to become a production base for manufacturing drugs specifically for the needs of China's military," Wang added.

[Related -Post Market Earning Scan: ORCL, RIMM, ACN, ADES, BSPM]

Biostar, through its subsidiary and controlled affiliate in China, develops, manufactures and markets pharmaceutical and health supplement products for a variety of diseases and conditions. Its most popular product is its Xin Aoxing Oleanolic Acid Capsule, an OTC medicine for chronic hepatitis B, a disease affecting about 10% of the Chinese population.

BSPM closed Monday's regular session at $0.98. The stock has been trading between $0.91 and $3.42 for the past 52 weeks.

iOnTheMarket Premium


Post Comment -- Login is required to post message
Alert for new comments:
Your email:
Your Website:

rss feed

Latest Stories

article imageThe Eurozone: On The Road To Recovery With A Lingering Risk

Back in September the idea that the Eurozone's economy could potentially undergo a recovery (see post) was read on...

article imageAversion to the Mean

Stocks’ gangbusters February doesn’t mean March must be a read on...

article imageNasdaq Back To 2000 Peak But What About Investors' Portfolios?

I hope Wall Street and CNBC don’t insult the intelligence of investors who were fully invested at the read on...

article imageStocks Break Out Again But May Be Running On Fumes

Despite low trading volume, a strong dollar, mixed economic and earnings reports, paralyzing weather read on...

Popular Articles

Daily Sector Scan
Partner Center

Fundamental data is provided by Zacks Investment Research, and Commentary, news and Press Releases provided by YellowBrix and Quotemedia.
All information provided "as is" for informational purposes only, not intended for trading purposes or advice. iStockAnalyst.com is not an investment adviser and does not provide, endorse or review any information or data contained herein.
The blog articles are opinions by respective blogger. By using this site you are agreeing to terms and conditions posted on respective bloggers' website.
The postings/comments on the site may or may not be from reliable sources. Neither iStockAnalyst nor any of its independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. You are solely responsible for the investment decisions made by you and the consequences resulting therefrom. By accessing the iStockAnalyst.com site, you agree not to redistribute the information found therein.
The sector scan is based on 15-30 minutes delayed data. The Pattern scan is based on EOD data.